sup 18^F-FDG PET SUVmax Correlates with Osteosarcoma Histologic Response to Neoadjuvant Chemotherapy: Preclinical Evaluation in an Orthotopic Rat Model

sup 18^F-FDG PET SUVmax Correlates with Osteosarcoma Histologic Response to Neoadjuvant Chemotherapy: Preclinical Evaluation in an Orthotopic Rat Model

Assessment of osteosarcoma response to neoadjuvant chemotherapy is performed by histopathologic analysis after surgical resection of the primary tumor. The purpose of this study was to evaluate whether ^sup 18^F-FDG PET could be a noninvasive surrogate to histopathologic analysis and allow for earli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of nuclear medicine (1978) 2009-09, Vol.50 (9), p.1533
Hauptverfasser: Dutour, Aurélie, Decouvelaere, Anne-Valérie, Monteil, Jacques, Duclos, Marie-Eve, Roualde, Olivier, Rousseau, Raphaël, Marec-Bérard, Perrine
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 9
container_start_page 1533
container_title The Journal of nuclear medicine (1978)
container_volume 50
creator Dutour, Aurélie
Decouvelaere, Anne-Valérie
Monteil, Jacques
Duclos, Marie-Eve
Roualde, Olivier
Rousseau, Raphaël
Marec-Bérard, Perrine
description Assessment of osteosarcoma response to neoadjuvant chemotherapy is performed by histopathologic analysis after surgical resection of the primary tumor. The purpose of this study was to evaluate whether ^sup 18^F-FDG PET could be a noninvasive surrogate to histopathologic analysis and allow for earlier response evaluation to neoadjuvant chemotherapy in osteosarcoma. Methods: Metabolic response to neoadjuvant chemotherapy was assessed in immunocompetent rats with a preestablished orthotopic osteosarcoma using ^sup 18^F-FDG PET before and after receiving 2 doses of ifosfamide. Comparison was then made by assessing histologic responses on euthanized animals. Results: Maximum standardized uptake value (SUVmax) measured by ^sup 18^F-FDG PET after 2 doses of chemotherapy was correlated to histologic classification (P < 0.01). An SUVmax less than 15 corresponded to good responders, whereas an SUVmax greater than 15 but less than 20 and an SUVmax greater than 20 corresponded to partial responders or nonresponders, respectively. A 40% decrease in SUVmax between the first and second ^sup 18^F-FDG PET scans distinguished between partial and good response to chemotherapy. Conclusion: Determination of SUV-max using semiquantitative ^sup 18^F-FDG PET predicts response to neoadjuvant chemotherapy earlier than does histologic analysis. [PUBLICATION ABSTRACT]
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_219227224</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1862979171</sourcerecordid><originalsourceid>FETCH-proquest_journals_2192272243</originalsourceid><addsrcrecordid>eNqNjMtOwzAQAC0EEuHxDyvukZIUp4FrSOiFtoLCkWqVLsSR4w32usCX8LuAxAdwmsOM5kAluZ7pVJfl_FAlWV7mqdaZPlYnIQxZlpVVVSXqK8QJ8uq5TdubW1g3G3h4fBrxA2r2niwKBXg30sMqCHFA3_GIsDBB2PKr6eCewsQuEAjDkhh3Q9yjE6h7Gll68jh9XsPaU2eNMx1aaPZoI4phB8YBOlh56Vl4-r2hwB3vyJ6poxe0gc7_eKou2mZTL9LJ81ukINuBo3c_alvkV0UxL4rL2b-ibycCWSM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219227224</pqid></control><display><type>article</type><title>sup 18^F-FDG PET SUVmax Correlates with Osteosarcoma Histologic Response to Neoadjuvant Chemotherapy: Preclinical Evaluation in an Orthotopic Rat Model</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Dutour, Aurélie ; Decouvelaere, Anne-Valérie ; Monteil, Jacques ; Duclos, Marie-Eve ; Roualde, Olivier ; Rousseau, Raphaël ; Marec-Bérard, Perrine</creator><creatorcontrib>Dutour, Aurélie ; Decouvelaere, Anne-Valérie ; Monteil, Jacques ; Duclos, Marie-Eve ; Roualde, Olivier ; Rousseau, Raphaël ; Marec-Bérard, Perrine</creatorcontrib><description>Assessment of osteosarcoma response to neoadjuvant chemotherapy is performed by histopathologic analysis after surgical resection of the primary tumor. The purpose of this study was to evaluate whether ^sup 18^F-FDG PET could be a noninvasive surrogate to histopathologic analysis and allow for earlier response evaluation to neoadjuvant chemotherapy in osteosarcoma. Methods: Metabolic response to neoadjuvant chemotherapy was assessed in immunocompetent rats with a preestablished orthotopic osteosarcoma using ^sup 18^F-FDG PET before and after receiving 2 doses of ifosfamide. Comparison was then made by assessing histologic responses on euthanized animals. Results: Maximum standardized uptake value (SUVmax) measured by ^sup 18^F-FDG PET after 2 doses of chemotherapy was correlated to histologic classification (P &lt; 0.01). An SUVmax less than 15 corresponded to good responders, whereas an SUVmax greater than 15 but less than 20 and an SUVmax greater than 20 corresponded to partial responders or nonresponders, respectively. A 40% decrease in SUVmax between the first and second ^sup 18^F-FDG PET scans distinguished between partial and good response to chemotherapy. Conclusion: Determination of SUV-max using semiquantitative ^sup 18^F-FDG PET predicts response to neoadjuvant chemotherapy earlier than does histologic analysis. [PUBLICATION ABSTRACT]</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>CODEN: JNMEAQ</identifier><language>eng</language><publisher>New York: Society of Nuclear Medicine</publisher><ispartof>The Journal of nuclear medicine (1978), 2009-09, Vol.50 (9), p.1533</ispartof><rights>Copyright Society of Nuclear Medicine Sep 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Dutour, Aurélie</creatorcontrib><creatorcontrib>Decouvelaere, Anne-Valérie</creatorcontrib><creatorcontrib>Monteil, Jacques</creatorcontrib><creatorcontrib>Duclos, Marie-Eve</creatorcontrib><creatorcontrib>Roualde, Olivier</creatorcontrib><creatorcontrib>Rousseau, Raphaël</creatorcontrib><creatorcontrib>Marec-Bérard, Perrine</creatorcontrib><title>sup 18^F-FDG PET SUVmax Correlates with Osteosarcoma Histologic Response to Neoadjuvant Chemotherapy: Preclinical Evaluation in an Orthotopic Rat Model</title><title>The Journal of nuclear medicine (1978)</title><description>Assessment of osteosarcoma response to neoadjuvant chemotherapy is performed by histopathologic analysis after surgical resection of the primary tumor. The purpose of this study was to evaluate whether ^sup 18^F-FDG PET could be a noninvasive surrogate to histopathologic analysis and allow for earlier response evaluation to neoadjuvant chemotherapy in osteosarcoma. Methods: Metabolic response to neoadjuvant chemotherapy was assessed in immunocompetent rats with a preestablished orthotopic osteosarcoma using ^sup 18^F-FDG PET before and after receiving 2 doses of ifosfamide. Comparison was then made by assessing histologic responses on euthanized animals. Results: Maximum standardized uptake value (SUVmax) measured by ^sup 18^F-FDG PET after 2 doses of chemotherapy was correlated to histologic classification (P &lt; 0.01). An SUVmax less than 15 corresponded to good responders, whereas an SUVmax greater than 15 but less than 20 and an SUVmax greater than 20 corresponded to partial responders or nonresponders, respectively. A 40% decrease in SUVmax between the first and second ^sup 18^F-FDG PET scans distinguished between partial and good response to chemotherapy. Conclusion: Determination of SUV-max using semiquantitative ^sup 18^F-FDG PET predicts response to neoadjuvant chemotherapy earlier than does histologic analysis. [PUBLICATION ABSTRACT]</description><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNjMtOwzAQAC0EEuHxDyvukZIUp4FrSOiFtoLCkWqVLsSR4w32usCX8LuAxAdwmsOM5kAluZ7pVJfl_FAlWV7mqdaZPlYnIQxZlpVVVSXqK8QJ8uq5TdubW1g3G3h4fBrxA2r2niwKBXg30sMqCHFA3_GIsDBB2PKr6eCewsQuEAjDkhh3Q9yjE6h7Gll68jh9XsPaU2eNMx1aaPZoI4phB8YBOlh56Vl4-r2hwB3vyJ6poxe0gc7_eKou2mZTL9LJ81ukINuBo3c_alvkV0UxL4rL2b-ibycCWSM</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>Dutour, Aurélie</creator><creator>Decouvelaere, Anne-Valérie</creator><creator>Monteil, Jacques</creator><creator>Duclos, Marie-Eve</creator><creator>Roualde, Olivier</creator><creator>Rousseau, Raphaël</creator><creator>Marec-Bérard, Perrine</creator><general>Society of Nuclear Medicine</general><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20090901</creationdate><title>sup 18^F-FDG PET SUVmax Correlates with Osteosarcoma Histologic Response to Neoadjuvant Chemotherapy: Preclinical Evaluation in an Orthotopic Rat Model</title><author>Dutour, Aurélie ; Decouvelaere, Anne-Valérie ; Monteil, Jacques ; Duclos, Marie-Eve ; Roualde, Olivier ; Rousseau, Raphaël ; Marec-Bérard, Perrine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_2192272243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dutour, Aurélie</creatorcontrib><creatorcontrib>Decouvelaere, Anne-Valérie</creatorcontrib><creatorcontrib>Monteil, Jacques</creatorcontrib><creatorcontrib>Duclos, Marie-Eve</creatorcontrib><creatorcontrib>Roualde, Olivier</creatorcontrib><creatorcontrib>Rousseau, Raphaël</creatorcontrib><creatorcontrib>Marec-Bérard, Perrine</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dutour, Aurélie</au><au>Decouvelaere, Anne-Valérie</au><au>Monteil, Jacques</au><au>Duclos, Marie-Eve</au><au>Roualde, Olivier</au><au>Rousseau, Raphaël</au><au>Marec-Bérard, Perrine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>sup 18^F-FDG PET SUVmax Correlates with Osteosarcoma Histologic Response to Neoadjuvant Chemotherapy: Preclinical Evaluation in an Orthotopic Rat Model</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><date>2009-09-01</date><risdate>2009</risdate><volume>50</volume><issue>9</issue><spage>1533</spage><pages>1533-</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><coden>JNMEAQ</coden><abstract>Assessment of osteosarcoma response to neoadjuvant chemotherapy is performed by histopathologic analysis after surgical resection of the primary tumor. The purpose of this study was to evaluate whether ^sup 18^F-FDG PET could be a noninvasive surrogate to histopathologic analysis and allow for earlier response evaluation to neoadjuvant chemotherapy in osteosarcoma. Methods: Metabolic response to neoadjuvant chemotherapy was assessed in immunocompetent rats with a preestablished orthotopic osteosarcoma using ^sup 18^F-FDG PET before and after receiving 2 doses of ifosfamide. Comparison was then made by assessing histologic responses on euthanized animals. Results: Maximum standardized uptake value (SUVmax) measured by ^sup 18^F-FDG PET after 2 doses of chemotherapy was correlated to histologic classification (P &lt; 0.01). An SUVmax less than 15 corresponded to good responders, whereas an SUVmax greater than 15 but less than 20 and an SUVmax greater than 20 corresponded to partial responders or nonresponders, respectively. A 40% decrease in SUVmax between the first and second ^sup 18^F-FDG PET scans distinguished between partial and good response to chemotherapy. Conclusion: Determination of SUV-max using semiquantitative ^sup 18^F-FDG PET predicts response to neoadjuvant chemotherapy earlier than does histologic analysis. [PUBLICATION ABSTRACT]</abstract><cop>New York</cop><pub>Society of Nuclear Medicine</pub></addata></record>
fulltext fulltext
identifier ISSN: 0161-5505
ispartof The Journal of nuclear medicine (1978), 2009-09, Vol.50 (9), p.1533
issn 0161-5505
1535-5667
language eng
recordid cdi_proquest_journals_219227224
source EZB-FREE-00999 freely available EZB journals
title sup 18^F-FDG PET SUVmax Correlates with Osteosarcoma Histologic Response to Neoadjuvant Chemotherapy: Preclinical Evaluation in an Orthotopic Rat Model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A42%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=sup%2018%5EF-FDG%20PET%20SUVmax%20Correlates%20with%20Osteosarcoma%20Histologic%20Response%20to%20Neoadjuvant%20Chemotherapy:%20Preclinical%20Evaluation%20in%20an%20Orthotopic%20Rat%20Model&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Dutour,%20Aur%C3%A9lie&rft.date=2009-09-01&rft.volume=50&rft.issue=9&rft.spage=1533&rft.pages=1533-&rft.issn=0161-5505&rft.eissn=1535-5667&rft.coden=JNMEAQ&rft_id=info:doi/&rft_dat=%3Cproquest%3E1862979171%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219227224&rft_id=info:pmid/&rfr_iscdi=true